Regeneron trades 9% below analyst target after EPS beat
Alpha Vantage · MarketBeat · · AI-summarised by FinFlash
Piper Sandler raised its Regeneron Pharmaceuticals price target to $865.00 from $854.00, keeping an overweight rating, implying roughly 10.7% upside from the current share price. The biopharma company recently beat analyst expectations with adjusted EPS of Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context